ethyl chloro oxalate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl chloro oxalate
• 英文别名: chloro-oxalic acid ethyl ester；2-O-chloro 1-O-ethyl oxalate
• 化学式: C₄H₅ClO₄
• 分子量: 152.534
• InChiKey: FDERFGRWXPPQPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl chloro oxalate 、 imino quinone 在 lead(IV) tetraacetate 作用下， 以 吡啶 、 二氯甲烷 、 溶剂黄146 、 乙酸乙酯 为溶剂， 以45%的产率得到苯并噻唑
  参考文献：
  名称：

  Photoactivated antiviral and antitumor compositions

  摘要：

  本文披露了一种用于使病毒失活并摧毁肿瘤细胞的化合物、组合物和方法。该方法涉及将含有光敏化学物质和能量捐赠化学物质的化合物加入到细胞中，这两者可以选择性地通过化学链相连。还向细胞中引入了化学激活能量捐赠化学物质的手段，该能量捐赠化学物质被激活后，再通过光活化光敏化学物质来摧毁肿瘤或病毒。光敏化学物质首选为金丝桃素、卟啉或类似物，而能量捐赠化学物质首选为荧光素或类似物。还披露了合成这些化学物质的方法。此外，能量捐赠化学物质由激活化学物质激活。激活化学物质的表达受到调控，以便瞄准受病毒感染或肿瘤细胞。通过多种方法调控激活化学物质的表达，包括构建一个含有编码激活化学物质的基因的表达质粒，该基因受到由病毒复制或肿瘤细胞中表达的蛋白质水平升高而转激活的启动子的控制。

  公开号：

  US05786198A1

文献信息

• Tricyclic quinoxalinediones
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US05616586A1

  公开（公告）日：1997-04-01

  Tricyclic quinoxalinediones of the formula: ##STR1## wherein X is alkyl, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, etc.; R.sup.1 is H, etc.; R.sup.2 is H, alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkylalkyl, arylalkyl, substituted arylalkyl, aryl, or substituted aryl; W is H, CO.sub.2 R.sup.3, CO.sub.2 Y, CONR.sup.3 R.sup.4, CONR.sup.3 Y, CON(OR.sup.3)R.sup.4, COR.sup.3, CN, tetrazolyl, or substituted alkyl; R.sup.3 and R.sup.4 independently are H, alkyl, cycloalkyl, alkenyl, alkynyl, etc.; Y is mono-substituted alkyl or di-substituted alkyl; and n is an integer 0 or 1, or a pharmaceutically acceptable salt thereof, which are useful as a selective antagonist of glutamate receptor for the treatment or prevention of various diseases in animals including human being, for example, minimizing damage of central nervous system induced by ischaemic or hypoxylic conditions, treatment and/or prevention of neurodegenerative disorders, and further analgesics, antidepressants, anxiolitics, and anti-schizophrenics.

  Tricyclic quinoxalinediones的中文翻译：其中X是烷基、卤素、氰基、三氟甲基、硝基、羟基、氨基等；R.sup.1是H等；R.sup.2是H、烷基、环烷基、烯基、炔基、环烷基烷基、芳基烷基、取代芳基烷基、芳基或取代芳基；W是H、CO.sub.2 R.sup.3、CO.sub.2 Y、CONR.sup.3 R.sup.4、CONR.sup.3 Y、CON(OR.sup.3)R.sup.4、COR.sup.3、CN、四唑基或取代烷基；R.sup.3和R.sup.4独立地是H、烷基、环烷基、烯基、炔基等；Y是单取代烷基或双取代烷基；n是整数0或1，或其药学上可接受的盐，可用作选择性谷氨酸受体拮抗剂，用于治疗或预防动物包括人类的各种疾病，例如，减少由缺血或低氧条件引起的中枢神经系统损伤，治疗和/或预防神经退行性疾病，以及进一步的镇痛剂、抗抑郁药、抗焦虑药和抗精神分裂症药物。
• Reactivity and regioselectivity in the acylation of 2,4-diaminoquinazolines
  作者：Elina Marinho、M. Fernanda Proença

  DOI：10.1016/j.tet.2016.06.003

  日期：2016.7

  at the phenylamino group by anhydrides, isocyanates or acyl chlorides, at room temperature. A similar selectivity was obtained in the reaction with ethoxymethylene derivatives and orthoesters. Acylation of the exocyclic imino substituent in the quinazolino-quinazoline tetracyclic structure also occurred under mild conditions with acetic anhydride and isocyanates. Hydrolysis to release the aniline substituent

  在室温下，通过酸酐，异氰酸酯或酰氯将2-（2-氨基苯基）喹唑啉-4-胺选择性地酰化在苯基氨基上。在与乙氧基亚甲基衍生物和原酸酯的反应中获得相似的选择性。在温和的条件下，用乙酸酐和异氰酸酯还可以使喹唑啉-喹唑啉四环结构中的环外亚氨基取代基酰化。用浓盐酸（在60°C下1当量）和3 M NaOH（3当量，rt）进行水解以释放苯胺取代基，从而生成甲酰化的衍生物或裂解杂环胺中的酰基。
• Cephalosporin derivatives
  申请人：Sankei Pharmaceutical Co., Ltd.

  公开号：US04808711A1

  公开（公告）日：1989-02-28

  There is disclosed a novel .beta.-lactam antibiotics represented by the formula: ##STR1## wherein A is a group represented by the formulae -NHCO--, --NHCONHCO--, --NHCOCH.dbd.CH-- or ##STR2## where R.sub.6 is a hydrogen atom or a lower alkyl group; R.sub.1 and R.sub.2 are independently a hydrogen atom or a protective group; R.sub.3 is a hydrogen atom or a methoxy group; X is a hydrogen atom, a hydroxyl group, a protected hydroxyl group, a halogen atom, a lower alkoxy group or a nitro group; n is an integer of 1 or 2; Y is a group represented by the formulae: ##STR3## provided that a carbon atom which is bonded by a carboxyl group being bonded to nitrogen atom; M is a hydrogen atom, a protective group or an easily hydrolyzable group in a human body; R.sub.7 is a hydrogen atom, a methyl group a lower alkoxy-methyl group or a group represented by the formula: --CH.sub.2 --T where T is an acyloxy group, a carbamoyloxy group, a quaternary ammonium, a substituted or unsubstituted heterocyclic ring or a formula: --S--R.sub.8 where R.sub.8 is an acyl group or a substituted or unsubstituted heterocyclic ring, R.sub.4 and R.sub.5 are each hydrogen atoms or combined with each other to form additional direct bond; Z is a direct bond or a carbonyl group when R.sub.4 and R.sub.5 are hydrogen atoms, or a formula: --O--B-- where the oxygen atom is bonded to nitrogen atom and B is a straight, branched or cyclic alkylene group when R.sub.4 and R.sub.5 are combined with each other to form additional direct bond, or its pharmaceutically acceptable salt.

  公开了一种新颖的β-内酰胺抗生素，其化学式表示为：其中A是由以下式表示的基团：-NHCO--、--NHCONHCO--、--NHCOCH.dbd.CH--或R.sub.6是氢原子或低碳基团；R.sub.1和R.sub.2分别是氢原子或保护基团；R.sub.3是氢原子或甲氧基；X是氢原子、羟基、保护羟基、卤素原子、低烷氧基或硝基；n是1或2的整数；Y是由以下式表示的基团：在此基团中，由羧基连接的碳原子与氮原子相连；M是氢原子、保护基团或在人体内易水解的基团；R.sub.7是氢原子、甲基、低烷氧基甲基或由以下式表示的基团：--CH.sub.2 --T，其中T是酰氧基、氨基甲酰氧基、季铵盐、取代或未取代的杂环环或式：--S--R.sub.8，其中R.sub.8是酰基或取代或未取代的杂环环，R.sub.4和R.sub.5分别是氢原子或结合在一起形成额外的直接键；Z是直接键或羰基，当R.sub.4和R.sub.5为氢原子时，或式：--O--B--，其中氧原子与氮原子相连，B是直链、支链或环烷基基团，当R.sub.4和R.sub.5结合在一起形成额外的直接键时，或其药用可接受盐。
• [EN] NOVEL INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS
  申请人：PROBIODRUG AG

  公开号：WO2014140279A1

  公开（公告）日：2014-09-18

  The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N- terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  该发明涉及一种具有式(I)的化合物或其药用可接受的盐、溶剂合物或多形体，包括其所有重质异构体和立体异构体，其中R1、R2、R3、R4和R5的定义如本文所述，作为谷氨酰环化酶（QC，EC 2.3.2.5）的抑制剂。QC催化N-末端谷氨酸残基向吡咯谷氨酸（5-氧代脯氨酰，pGlu*）的分子内环化，释放氨，并催化N-末端谷氨酸残基向吡咯谷氨酸的分子内环化，释放水。
• Novel resorcinol ethers and anti-inflammatory and anti-allergic use
  申请人：Ciba-Geigy Corporation

  公开号：US04863942A1

  公开（公告）日：1989-09-05

  Novel 4-acylresorcinol ethers of the formula ##STR1## in which R.sub.1 represents lower alkyl, R.sub.2 represents lower alkyl, lower alkenyl or lower alkynyl, R.sub.3 represents hydrogen, lower alkoxy, trifluoromethyl or halogen, alk represents an alkylene radical, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.9 and a radical R.sub.7 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.10, R.sub.6 represents hydrogen, lower alkyl, halogen, trifluoromethyl, optionally esterified or amidated carboxy, cyano or lower alkanoyl, R.sub.8 represents optionally esterified or amidated carboxy, or 5-tetrazolyl, R.sub.9 represents hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R.sub.10 represents hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or optionally esterified or amidated carboxy, and their salts have LTD.sub.4 -antagonistic and PLA.sub.2 -phospholipase-inhibiting properties. They can be manufactured according to methods known per se.

  该公式的小说4-酰基邻苯二酚醚化合物，其中R.sub.1代表较低的烷基，R.sub.2代表较低的烷基，较低的烯基或较低的炔基，R.sub.3代表氢，较低的烷氧基，三氟甲基或卤素，alk代表烷基基团，其中R.sub.4，R.sub.5和R.sub.7中的一个基团是--NH--C(.dbd.O)--R.sub.8的基团，除了--NH--C(.dbd.O)--R.sub.8的基团是R.sub.9的基团和除了--NH--C(.dbd.O)--R.sub.8的基团是R.sub.10的基团之外，R.sub.6代表氢，较低的烷基，卤素，三氟甲基，可选地酯化或酰胺化的羧基，氰基或较低的烷酰基，R.sub.8代表可选地酯化或酰胺化的羧基，或5-四氮唑基，R.sub.9代表氢，较低的烷基，较低的烷氧基，卤素或三氟甲基，R.sub.10代表氢，较低的烷基，较低的烷氧基，卤素，三氟甲基，氰基或可选地酯化或酰胺化的羧基，它们的盐具有LTD.sub.4-拮抗和PLA.sub.2-磷脂酶抑制性能。它们可以根据已知方法制造。